Oppenheimer Holdings Inc. restated their outperform rating on shares of Eiger BioPharmaceuticals Inc. (NASDAQ:EIGR) in a research note released on Monday morning. They currently have a $34.00 target price on the stock.
Several other equities research analysts have also commented on the company. Jefferies Group restated a buy rating and issued a $33.00 price objective on shares of Eiger BioPharmaceuticals in a research note on Thursday, October 20th. Wedbush restated an outperform rating and issued a $36.00 price objective (up from $34.00) on shares of Eiger BioPharmaceuticals in a research note on Tuesday, November 8th. Finally, Zacks Investment Research lowered Eiger BioPharmaceuticals from a hold rating to a sell rating in a research note on Thursday, November 10th. One research analyst has rated the stock with a sell rating and four have given a buy rating to the stock. The stock currently has an average rating of Buy and a consensus target price of $34.00.
Shares of Eiger BioPharmaceuticals (NASDAQ:EIGR) opened at 12.75 on Monday. The firm’s 50-day moving average price is $12.45 and its 200 day moving average price is $16.69. Eiger BioPharmaceuticals has a 52 week low of $10.71 and a 52 week high of $28.35. The company’s market cap is $106.54 million.
In other Eiger BioPharmaceuticals news, Director Jeffrey S. Glenn purchased 15,460 shares of the business’s stock in a transaction on Friday, November 18th. The stock was acquired at an average price of $12.74 per share, for a total transaction of $196,960.40. Following the purchase, the director now owns 16,355 shares of the company’s stock, valued at approximately $208,362.70. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 27.20% of the stock is owned by company insiders.
A number of large investors have recently modified their holdings of EIGR. Jacobs Levy Equity Management Inc. acquired a new stake in shares of Eiger BioPharmaceuticals during the first quarter worth about $251,000. Bank of New York Mellon Corp acquired a new stake in shares of Eiger BioPharmaceuticals during the second quarter worth about $214,000. California State Teachers Retirement System acquired a new stake in shares of Eiger BioPharmaceuticals during the second quarter worth about $144,000. Vanguard Group Inc. increased its position in Eiger BioPharmaceuticals by 265.6% in the second quarter. Vanguard Group Inc. now owns 124,787 shares of the company’s stock valued at $2,473,000 after buying an additional 90,659 shares during the period. Finally, BlackRock Investment Management LLC increased its position in Eiger BioPharmaceuticals by 4,942.9% in the second quarter. BlackRock Investment Management LLC now owns 12,355 shares of the company’s stock valued at $245,000 after buying an additional 12,110 shares during the period. Institutional investors and hedge funds own 39.95% of the company’s stock.
About Eiger BioPharmaceuticals